Actively Recruiting

Age: 18Years +
All Genders
ID05914987

Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)

Led by Medical College of Wisconsin · Updated on 2026-05-05

1000

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore precision oncology for adults with pancreatic cancer by collecting and analyzing data to understand how personalized treatments based on molecular tumor profiling work. The study evaluates how well molecular testing predicts patient responses to targeted therapies and assesses outcomes like tumor response, time to treatment failure, survival, and treatment tolerability. The study is observational and non-therapeutic, examining patient medical records both retrospectively and prospectively. It focuses on examining results from molecular profiling obtained through standard care to guide targeted therapy decisions. Approved targeted therapies based on each patient's genomic profile are considered by investigators for potential anti-tumor treatment. Participants will have their demographic and clinical data reviewed, including tumor response and survival outcomes. Researchers will monitor how many subjects receive targeted therapy over five years. The study involves no direct intervention or treatment administration by the research team. Participation includes data collection from medical records and ongoing tracking of treatment outcomes to better understand personalized therapy in pancreatic cancer.

CONDITIONS

Brief Title

Determining Individualized Cancer Therapy in Pancreatic Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 218 years.
  • Pathologically confirmed pancreatic cancer.
  • Ability to understand and willingness to sign a written informed consent document.
Not Eligible

You will not qualify if you...

  • Age <18 years.
  • Primary cancer diagnosis other than pancreatic cancer.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - Initial assessment period

Participants undergo genomic profiling to determine individualized cancer therapy options based on their pancreatic cancer.

Long-term Monitoring

Duration - Up to 5 years

Participants are observed over time to assess the use and outcomes of targeted therapies guided by their genomic profile.

Trial Site Locations

Total: 1 location

1

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

C

Cancer Center Clinical Trials Office

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Pancreatic Cancer Screening Study in Hereditary High Risk ...

Pancreatic Neoplasms

Actively Recruiting

1 location

Pancreatic Cancer Screening Study in People With New-Onset o...

Pancreatic Cancer

Actively Recruiting

2 locations

A Phase I/II Trial of UCB4594 to Assess Safety, Pharmacokine...

Advanced Solid Tumours

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here